June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Change in the Deflection of the Neural Canal Opening Over Time with Acetazolamide Treatment in Idiopathic Intracranial Hypertension
Author Affiliations & Notes
  • Jui-Kai Wang
    Department of Electrical and Computer Engineering, The University of Iowa, Iowa City, IA
  • Patrick A Sibony
    Department of Ophthalmology, State University of NY at Stony Brook/UHMC, Stony Brook, NY
  • Randy H Kardon
    Department of Ophthalmology and Visual Sciences, The University of Iowa, Iowa City, IA
    Center for the Prevention and Treatment of Visual Loss, Iowa City VA Health Care System, Iowa City, IA
  • Mark J Kupersmith
    Department of Neuro-Ophthalmology, Roosevelt Hospital and NYEE, New York, NY
  • Mona K Garvin
    Department of Electrical and Computer Engineering, The University of Iowa, Iowa City, IA
    Center for the Prevention and Treatment of Visual Loss, Iowa City VA Health Care System, Iowa City, IA
  • Footnotes
    Commercial Relationships Jui-Kai Wang, None; Patrick Sibony, None; Randy Kardon, Acorda (C), Department of Veterans Affairs Research Foundation, Iowa City, IA (S), Fight for Sight Inc (S), Novartis (C); Mark Kupersmith, None; Mona Garvin, The University of Iowa (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2233. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jui-Kai Wang, Patrick A Sibony, Randy H Kardon, Mark J Kupersmith, Mona K Garvin, IIHTT OCT Sub-Study Committee, NORDIC Idiopathic Intracranial Hypertension Study Group; Change in the Deflection of the Neural Canal Opening Over Time with Acetazolamide Treatment in Idiopathic Intracranial Hypertension. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2233.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

In papilledema, Bruch’s membrane (BM) bordering the neural canal opening is often deflected inward toward the vitreous in contrast to normal eyes (Sibony et al., IOVS, 2011, 2014). We prospectively compared OCT-derived changes in the BM shape with acetazolamide (ACZ) plus diet compared to placebo plus diet in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). A novel semi-automated method for quantifying the BM shape was developed for this purpose.

 
Methods
 

For each of the 126 subjects enrolled in the OCT substudy of the IIHTT (OCT Sub-Study Committee, IOVS, 2014), the central slice from the Cirrus OCT high-definition (HD) 5-line raster scan at baseline, 3 months, and 6 months (as available) was used to perform the statistical shape analysis. After manually marking the two Bruch’s membrane opening points in each slice, 9 landmark points were automatically placed along Bruch’s membrane on each side of the neural canal border, extending out radially for 2500 microns (Fig. 1). Principal component analysis was used to create a shape model using the landmark points at baseline. The second principal component coefficient, reflecting the angle and direction of the neural canal border, was then computed at each time point for study eyes in the two treatment groups.

 
Results
 

In this analysis, 73 out of 126 subjects in IIHTT OCT substudy had 5-line raster data available at all time points for the study eye. In the ACZ plus diet group (n=39), the neural canal shape measure became more positive (deflecting away from the vitreous cavity, Fig. 2 left) over time and was significantly greater (p < 0.01) than in the placebo plus diet group (n=34), as shown in Fig. 2. The mean neural canal shape measure changes from baseline to 3 months were 0.64 ± 1.10 in the ACZ group vs. -0.04 ± 0.93 in the placebo group; from baseline to 6 months, the changes were 0.87 ± 1.26 in the ACZ group vs. 0.03 ± 0.83 in the placebo group.

 
Conclusions
 

Displacement of the neural canal border at the optic nerve head reflects the translaminar pressure differential between the retrolaminar and intraocular fluid compartments and appears to be a biomarker of successful treatment of raised intracranial pressure.  

 
Fig. 1. Semi-automated landmark placement
 
Fig. 1. Semi-automated landmark placement
 
 
Fig. 2. Left: Neural canal shape model variations; Right: Shape measure in ACZ/placebo group at baseline, 3 months and 6 months
 
Fig. 2. Left: Neural canal shape model variations; Right: Shape measure in ACZ/placebo group at baseline, 3 months and 6 months

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×